clinical trial · NCT05564039
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
Eli Lilly and Company·phase4·completed·n = 282
Type 2 DiabetesTirzepatideDulaglutide
brief summary
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
started
Nov 30, 2022
primary completion
Jul 15, 2024
completion
Aug 12, 2024
last updated
Aug 3, 2025
official title
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol